Gland Pharma Ltd to Hold Board Meeting for Q1 2026 Results; Investor Call Scheduled
Gland Pharma Limited has announced that its Board of Directors will convene a meeting to consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026.The Board meeting is scheduled to take place on Monday, August 10, 2026. In addition to reviewing the financial outcomes, the company has set an Investor/Analyst call for the same day.
The details regarding the upcoming corporate events are as follows:
| Event | Date | Time | Purpose / Details |
|---|---|---|---|
| Board Meeting | Monday, August 10, 2026 | N/A | Consideration and approval of Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026. |
| Investor/Analyst Call | Monday, August 10, 2026 | 18:30 Hrs (IST) | Discussion related to the financial results. |
| Trading Window Reopening | Thursday, August 13, 2026 | N/A | The trading window will reopen following its closure on Saturday, June 27, 2026. |
The company noted that further details regarding the Investor/Analyst call will be provided to stock exchanges and published on its official website in due course.
GLAND Stock Price Movement
On Friday, Gland Pharma Limited shares edged higher to settle at ₹2379.80, rising 0.43% in the trading session. The stock achieved this gain of ₹10.30 on a volume of 156,545 shares, closing within its daily range after starting near the previous day’s close.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.